Nasdaq:CMPS
COMPASS Pathways plc
A commercial-stage biopharmaceutical developer creating first-in-class treatments for severe mental illness with significant cash reserves but no current product revenue.
Key Metrics
Investment Thesis
Bull Case
CMPS offers a high-conviction binary option on a potential blockbuster asset in the lucrative US insomnia and anxiety market with minimal current competition. The substantial cash runway allows the company to weather regulatory hurdles and complete large Phase 3 trials without immediate need for emergency fundraising, preserving shareholder value. Successful commercialization of the DORA asset could result in significant multiple expansion as the first new treatment class in decades hits the market.
Bear Case
Investors face extreme volatility risk given the binary nature of biotech development where a single failed trial can wipe out a large portion of the company's equity value. The current financials show an annualized cash burn that is unsustainable without successful product launches or significant external capital raises, leading to inevitable dilution. There is no near-term revenue visibility, making the stock valuation purely speculative based on potential future outcomes rather than current fundamentals.
About COMPASS Pathways plc
COMPASS Pathways plc (CMPS) is a commercial-stage biopharmaceutical company developing novel therapies for severe mental illness and addiction. The company focuses on its proprietary dual orexin receptor 1/2 antagonist (DORA), currently in Phase 3 trials, targeting the large US market for treatment-resistant insomnia and anxiety disorders. While currently pre-revenue, the firm leverages a substantial cash position to fund high-risk, high-reward research aimed at transforming psychiatric care.
Analysis
Management Discussion
The company reported a net loss of $155.1M for the latest period, driven primarily by research and development expenses totaling $119.0M and general administrative costs of $59.2M. Despite these losses, cash flow from operations was negative due to high burn rates, yet the company maintained a robust cash position with ending cash equivalents of $165.5M and utilized financing activities including share issuances to extend its runway. Operating profit remained negative at -$178.2M reflecting the capital-intensive nature of pre-revenue biopharmaceutical development.
Industry Overview
The global mental health and insomnia treatment market is expanding rapidly as patient awareness grows and regulatory pathways for new indications open up. The industry is currently facing a shortage of novel mechanisms of action beyond existing benzodiazepines and Z-drugs, creating an urgent unmet medical need that dual orexin antagonists aim to fill. Success in this sector depends heavily on clinical trial execution, safety data in complex patient populations, and the ability to secure favorable reimbursement rates from payers.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $110.4M | $136.9M | $178.2M |
| Operating Income | $-110.4M | $-136.9M | $-178.2M |
| R&D | $65.1M | $87.5M | $119.0M |
| G&A | $45.4M | $49.4M | $59.2M |
| Stock-Based Comp | $13.1M | $17.3M | $19.5M |
| D&A | $330.0K | $242.0K | — |
| Depreciation | — | — | $233.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $19.3M | $19.2M | $24.7M |
| Interest Expense | — | $2.2M | — |
| Interest Income | — | — | $8.3M |
| Pre-Tax Income | $-91.1M | $-117.7M | $-153.5M |
| Income Tax | $408.0K | $780.0K | $1.6M |
| Continuing Ops | $-91.5M | $-118.5M | $-155.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-91.5M | $-118.5M | $-155.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-91.5M | $-118.5M | $-155.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $191.7M | $261.3M | $201.3M |
| Cash & Equivalents | $143.2M | $220.2M | $165.1M |
| Prepaid Expenses | $47.7M | $39.5M | $35.8M |
| Other Current Assets | $750.0K | $1.6M | $389.0K |
| Long-Term Assets | $5.6M | $14.7M | $12.4M |
| PP&E (Net) | $617.0K | $423.0K | $189.0K |
| Operating Leases | $2.0M | $4.3M | $2.0M |
| Other LT Assets | $3.0M | $10.0M | $10.2M |
| Total Assets | $197.3M | $276.0M | $213.7M |
| Current Liabilities | $15.6M | $19.6M | $34.0M |
| Accounts Payable | $4.8M | $5.9M | $12.3M |
| Current Debt | — | — | $5.5M |
| Current Leases | $1.5M | $2.4M | $1.7M |
| Taxes Payable | — | — | $0 |
| Other Current Liab | $9.3M | $11.3M | $14.5M |
| Long-Term Liabilities | $418.0K | $30.6M | $25.0M |
| Long-Term Debt | — | — | $24.7M |
| LT Operating Leases | $418.0K | $1.9M | $303.0K |
| Other LT Liab | $0 | $28.8M | $0 |
| Total Liabilities | $16.0M | $50.2M | $59.0M |
| Shareholders' Equity | $181.3M | $225.7M | $154.7M |
| Paid-In Capital | $458.8M | $621.6M | $704.9M |
| Retained Earnings | $-261.1M | $-379.6M | $-534.7M |
| AOCI | $-16.9M | $-16.9M | $-16.2M |
| Total L&E | $197.3M | $276.0M | $213.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-91.5M | $-118.5M | $-155.1M |
| Non-Cash Adjustments | $-44.8M | $23.5M | $32.3M |
| Working Capital Changes | $30.9M | $-2.4M | $3.6M |
| Cash from Operations | $-105.5M | $-97.4M | $-119.2M |
| Capital Expenditures | $596.0K | $66.0K | $0 |
| Cash from Investing | $-596.0K | $-64.0K | $0 |
| Debt Issuances | — | $29.6M | $0 |
| Cash from Financing | $1.0M | $173.8M | $63.8M |
| FX Effect | $-25.0M | $867.0K | $194.0K |
| Net Change in Cash | $-130.0M | $77.3M | $-55.2M |
| Beginning Cash | $273.3M | $143.4M | $220.6M |
| Ending Cash | $143.4M | $220.6M | $165.5M |
Frequently Asked Questions
How does COMPASS Pathways plc make money?
The company's operations are centered on its lead asset, a dual orexin receptor antagonist (DORA) intended to treat insomnia and anxiety associated with psychiatric conditions. Given the lack of cost of revenue and gross profit in the latest period, all financial activity is driven by research and development expenditures and general administrative costs rather than commercial sales.
What are the main risks for CMPS?
Complete reliance on future commercial success as the company currently generates no revenue and burns significant cash annually. High probability of Phase 3 trial failure or delayed regulatory approval which would necessitate further equity dilution or asset sales. Potential for adverse clinical data regarding safety profiles in patients with comorbid psychiatric conditions. Market competition from established sleep disorder therapies that may limit pricing power upon launch.
What is CMPS's competitive advantage?
First-in-class mechanism of action with a dual orexin receptor antagonist profile that addresses both sleep and anxiety pathways simultaneously. Strong balance sheet liquidity providing over $165M in cash to sustain R&D through the critical Phase 3 trial completion and potential regulatory approval. Experienced management team with a proven track record in de-risking novel psychiatric asset classes.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.